Insider Selling: CymaBay Therapeutics Inc (CBAY) Director Sells 40,763 Shares of Stock

CymaBay Therapeutics Inc (NASDAQ:CBAY) Director Kurt Von Emster sold 40,763 shares of CymaBay Therapeutics stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $12.35, for a total transaction of $503,423.05. Following the sale, the director now owns 90,000 shares in the company, valued at $1,111,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Kurt Von Emster also recently made the following trade(s):

  • On Monday, February 5th, Kurt Von Emster sold 18,831 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $12.14, for a total transaction of $228,608.34.
  • On Friday, February 2nd, Kurt Von Emster sold 90,098 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $12.15, for a total transaction of $1,094,690.70.
  • On Wednesday, January 31st, Kurt Von Emster sold 97,639 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $12.22, for a total transaction of $1,193,148.58.
  • On Thursday, January 25th, Kurt Von Emster sold 39,438 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $12.18, for a total transaction of $480,354.84.
  • On Monday, January 22nd, Kurt Von Emster sold 138,253 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $10.40, for a total transaction of $1,437,831.20.
  • On Friday, January 19th, Kurt Von Emster sold 144,216 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $10.25, for a total transaction of $1,478,214.00.
  • On Friday, January 5th, Kurt Von Emster sold 4,300 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $10.21, for a total transaction of $43,903.00.
  • On Friday, December 22nd, Kurt Von Emster sold 173,192 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $9.41, for a total transaction of $1,629,736.72.

Shares of CymaBay Therapeutics Inc (CBAY) traded down $0.29 on Friday, reaching $11.71. The company had a trading volume of 1,450,404 shares, compared to its average volume of 930,983. The stock has a market cap of $513.65, a PE ratio of -11.59 and a beta of 2.04. CymaBay Therapeutics Inc has a 1 year low of $2.19 and a 1 year high of $13.25. The company has a debt-to-equity ratio of 0.04, a current ratio of 7.39 and a quick ratio of 7.39.

CymaBay Therapeutics (NASDAQ:CBAY) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.02). During the same period in the previous year, the firm earned ($0.25) earnings per share. equities analysts anticipate that CymaBay Therapeutics Inc will post -0.87 EPS for the current year.

Several equities research analysts have commented on CBAY shares. Oppenheimer set a $15.00 price target on shares of CymaBay Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, January 10th. Zacks Investment Research cut shares of CymaBay Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, January 16th. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of CymaBay Therapeutics in a research report on Tuesday, November 28th. Piper Jaffray Companies reiterated a “buy” rating and issued a $12.00 price target on shares of CymaBay Therapeutics in a research report on Friday, October 27th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $16.00 price target on shares of CymaBay Therapeutics in a research report on Wednesday, November 8th. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. CymaBay Therapeutics has an average rating of “Buy” and a consensus target price of $16.56.

Institutional investors and hedge funds have recently modified their holdings of the stock. Boothbay Fund Management LLC purchased a new position in CymaBay Therapeutics in the 3rd quarter worth about $404,000. Perceptive Advisors LLC purchased a new position in CymaBay Therapeutics in the 3rd quarter worth about $18,948,000. Bank of New York Mellon Corp increased its stake in CymaBay Therapeutics by 794.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 155,174 shares of the biopharmaceutical company’s stock worth $1,251,000 after purchasing an additional 137,830 shares in the last quarter. Ardsley Advisory Partners increased its stake in CymaBay Therapeutics by 66.2% in the 2nd quarter. Ardsley Advisory Partners now owns 50,210 shares of the biopharmaceutical company’s stock worth $290,000 after purchasing an additional 20,000 shares in the last quarter. Finally, EAM Investors LLC purchased a new position in CymaBay Therapeutics in the 3rd quarter worth about $4,788,000. 54.70% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/09/insider-selling-cymabay-therapeutics-inc-cbay-director-sells-40763-shares-of-stock.html.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Insider Buying and Selling by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply